FC
IOVA icon

Farringdon Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Farringdon Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,278
Closed -$19.4K – 555
2025
Q2 		$19.4K Buy
+11,278
New +$28.1K 0.01% 421

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Farringdon Capital's IOVA Position: Q3 2025 in Review

Farringdon Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 11,278 shares — an estimated $19.4K sold.

Farringdon Capital first reported a position in IOVA in Q2 2025 and held it in 1 quarter. The position peaked at $19.4K in Q2 2025. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Farringdon Capital reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Farringdon Capital sold 11,278 Iovance Biotherapeutics shares in Q3 2025, an estimated $19.4K.
  • Farringdon Capital first reported a position in Iovance Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Farringdon Capital's Iovance Biotherapeutics position peaked at $19.4K in Q2 2025.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Farringdon Capital's 13F filing for Q3 2025, filed 13 Nov 2025.